When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent ...

   www.aol.com/pfizer-eyes-20-billion-revenue...

   On the cost side, Pfizer achieved $4 billion in savings and announced an additional $1.5 billion in margin improvements. In R&D, leadership changed for the first time in 15 years,

3. Barbasol - Wikipedia

   en.wikipedia.org/wiki/Barbasol

   As gels became popular, Pfizer created gel versions of Barbasol in the Original, Soothing Aloe, Sensitive Skin, and Extra Protection varieties. In the 1980s, Pfizer made Barbasol Glide Stick, a deodorant. By the 1990s, Barbasol brand equity had diminished. Sales had slowed. Pfizer, primarily a pharmaceutical company, looked to sell the brand.

4. What activist hedge fund Starboard wants from Pfizer - AOL

   www.aol.com/activist-hedge-fund-starboard-met...

   Smith hasn't yet said whether he wants board seats at Pfizer, but the 52-year-old Starboard cofounder has served on the board of companies his hedge fund has targeted before, including pizza chain ...

5. Is This Decision by Pfizer Bad News for Eli Lilly? - AOL

   www.aol.com/decision-pfizer-bad-news-eli...

   Is this latest move by Pfizer bad news for Lilly? Let's find out. An investor studies something on a laptop in a kitchen. Image source: Getty Images. Struggling to meet demand.

6. Pfizer's bladder cancer therapy meets main goal in late-stage ...

   www.aol.com/news/pfizers-bladder-cancer-therapy...

   Pfizer said it plans to present the data at an upcoming medical meeting and discuss it with global health regulators for a potential approval. Pfizer's bladder cancer therapy meets main goal in ...

7. Seagen acquisition will give Pfizer 'anchor asset' Wall ... - AOL

   www.aol.com/finance/seagen-acquisition-pfizer...

   But Pfizer took it off the market in 2010 after study results showed the dosage being used was more toxic than chemotherapy. In 2017, Pfizer was able to bring back a lower dose of the drug for use ...

8. Pfizer's Oxbryta exit may hasten trials of rival experimental ...

   www.aol.com/news/pfizers-oxbryta-exit-may-hasten...

   Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said. Oxbryta ...

9. Pfizer trims expectations for 2023 with sales of COVID-19 ...

   www.aol.com/news/pfizer-cuts-full-outlook-due...

   Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue ...